Grant ID RP190236
Awarded On February 21, 2019
Title Role of PARP-1 in Estrogen Receptor Enhancer Function and Gene Regulation Outcomes in Breast Cancers
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director W. Lee Kraus
Cancer Sites Breast
Contracted Amount $899,397
Lay Summary

A key hurdle in developing better treatments for breast cancers is a lack of understanding of the mechanisms that promote their growth, and why some breast cancers grow in response to estrogens, while others do not. Olaparib, a drug that targets PARP-1, a protein involved in many important cellular functions, was recently approved by the FDA for the treatment of breast cancers with certain types of DNA repair defects. Preliminary results suggest that Olaparib and other PARP inhibitors may also be useful for treating breast cancers that express estrogen receptor alpha (ERa) and are responsive to the hormone estrogen. In this regard, we are studying the interplay between ERa and PARP-1 in ...

Read More